

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

SAFETY DATA SHEET

MAPCOAT BASE GREY A3610

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1	Pro	duct	identifier	
_				

Product name SDS code : MAPCOAT BASE GREY A3610 : 21130000B

1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses			
Paint. Professional use Industrial use				
Uses advised against				
All other uses				
Draduatuaa	 Solvent herne coeting for exterior use 			

Product use

: Solvent borne coating for exterior use.

1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

1.4 Emergency telephone number

National advisory body/Poison Center					
Telephone number : +33 (0)1 40 05 48 48					
<u>Supplier</u>					
Telephone number	: +33 (0)5 34 01 34 01				
	+33 (0)5 61 60 23 30				
Hours of operation	:				

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H335 STOT RE 2, H373 Aquatic Chronic 3, H412



SECTION 2: Hazards identification

÷

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 16 for the full text of the H statements declared above. See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



		•	•	
Signal word	:	Warning		
Hazard statements	:	Flammable liquid and vapor. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. Harmful if inhaled. May cause respiratory irritation. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.		
Precautionary statements				
Prevention	:	surfaces, sparks, open f	Wear eye or face protection. Ke lames and other ignition source ent. Do not breathe vapor. Was	s. No smoking. Avoid
Response	:	CENTER or doctor if you before reuse. IF ON SK occurs: Get medical adv several minutes. Remov	tention if you feel unwell. IF INH a feel unwell. Take off contamin IN: Wash with plenty of water. I ice or attention. IF IN EYES: Ri e contact lenses, if present and Get medical advice or attention.	ated clothing and wash it f skin irritation or rash nse cautiously with water for
Storage	:	Store in a well-ventilated	l place. Keep container tightly cl	osed. Keep cool.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.		
Hazardous ingredients	:	Reaction mass of ethylb 1,6-hexanediyl-bis(2-(2- dibutyltin dilaurate	enzene and xylene (1-ethylpentyl)-3-oxazolidinyl)eth	yl)carbamate
Supplemental label elements	:	Not applicable.		
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.		
Special packaging requirem	en	<u>ts</u>		
Containers to be fitted with child-resistant fastenings	:	Not applicable.		
Tactile warning of danger	:	Not applicable.		
2.3 Other hazards				
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not co vPvB.	ontain any substances that are a	ssessed to be a PBT or a
Date of issue/Date of revision		: 1-11-2022	Version : 1.01	
Date of previous issue		: 1-10-2022	2/20	AkzoNobel

SECTION 2: Hazards identification

Other hazards which do : None known. not result in classification

SECTION 3: Composition/information on ingredients

3.2 Mixtures

: Mixture

Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32	≥25 - ≤50	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
aromatic hydrocarbons, C9	REACH #: 01-2119455851-35 EC: 918-668-5 CAS: 128601-23-0	≥10 - ≤15	Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 EUH066	[1]
1,6-hexanediyl-bis(2-(2- (1-ethylpentyl)-3-oxazolidinyl)ethyl) carbamate	REACH #: 01-2119890830-32 EC: 411-700-4 CAS: 140921-24-0 Index: 616-079-00-5	≤5	Skin Sens. 1, H317	[1]
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≤0.8	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
cyclohexanone	REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7	<1	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.4	Asp. Tox. 1, H304 EUH066	[1]
dibutyltin dilaurate	REACH #: 01-2119496068-27 EC: 201-039-8 CAS: 77-58-7	≤0.1	Eye Irrit. 2, H319 Skin Sens. 1, H317 Muta. 2, H341 Repr. 1B, H360FD STOT SE 1, H370 (thymus) STOT RE 1, H372 (immune system) Aquatic Acute 1, H400 (M=1) Aquatic Chronic 1, H410 (M=1) See Section 16 for the full text of the H	[1] [2]

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	3/20	AkzoNobel

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 MAPCOAT BASE GREY A3610

SECTION 3: Composition/information on ingredients

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit
- [3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII
- [4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII
- [5] Substance of equivalent concern
- [6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Skin contact	:	Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention following exposure or if feeling unwell. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01
Date of previous issue	: 1-10-2022	4/20



SECTION 4: First aid measures

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains 1,6-hexanediyl-bis(2-(2-(1-ethylpentyl)-3-oxazolidinyl)ethyl)carbamate, dibutyltin dilaurate. May produce an allergic reaction.

Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: respiratory tract irritation coughing
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	: In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising	om the substance or mixture
Hazards from the substance or mixture	: Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide nitrogen oxides halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Date of issue/Date of revision	: 1-11-2022 Version : 1 01

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	5/20	AkzoNobe

SECTION 5: Firefighting measures				
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.			

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.
6.3 Methods and materials for	r c	ontainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapor or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain
	

Date of issue/Date of revision	: 1-11-2022	Version : 1.01
Date of previous issue	: 1-10-2022	6/20



SECTION 7: Handling and storage

product residue and can be hazardous. Do not reuse container.

Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
--	---

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

Seveso Directive - Reporting thresholds

Danger criteria

	Notification and MAPP threshold	Safety report threshold
P5c	5000 tonne	50000 tonne

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient	t name	Exposure limit values	6		
Reaction mass of ethylbenzend	e and xylene	Ministry of Labor (France, 3/2020). Absorbed through skin. Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 442 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 100 ppm 15 minutes. Form: Risk for sensitisation TWA: 221 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 50 ppm 8 hours. Form: Risk for sensitisation			
n-butyl acetate		TWA: 50 ppm 8 hours. Form: Risk for sensitisation Ministry of Labor (France, 3/2020). Notes: Indicative limit values (circular) STEL: 940 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 200 ppm 15 minutes. Form: Risk for sensitisation TWA: 710 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 150 ppm 8 hours. Form: Risk for sensitisation			
cyclohexanone		Ministry of Labor (France, 3/2020). Notes: Binding regulatory limit values (article R. 4412-149 of the Labor Code) STEL: 81.6 mg/m ³ 15 minutes. Form: Risk for sensitisation STEL: 20 ppm 15 minutes. Form: Risk for sensitisation TWA: 40.8 mg/m ³ 8 hours. Form: Risk for sensitisation TWA: 10 ppm 8 hours. Form: Risk for sensitisation			
dibutyltin dilaurate		Ministry of Labor (France, 3/2020). Notes: Indicative limit values (circular) STEL: 0.2 mg/m³, (as Sn) 15 minutes. Form: Risk for sensitisation			
Date of issue/Date of revision	: 1-11-2022	Version : 1.01			
Date of previous issue	:1-10-2022	0-2022 7/20 AkzoNobel			

SECTION 8: Exposure controls/personal protection TWA: 0.1 mg/m³, (as Sn) 8 hours. Form: Risk for sensitisation : If this product contains ingredients with exposure limits, personal, workplace **Recommended monitoring** atmosphere or biological monitoring may be required to determine the effectiveness procedures of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Population	Effects
Reaction mass of ethylbenzene and	DNEL	Long term Oral	1.6 mg/kg	General	Systemic
xylene			bw/day	population	
	DNEL	Long term	14.8 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Long term	77 mg/m³	Workers	Systemic
		Inhalation		•	
	DNEL	Long term Dermal	108 mg/kg	General	Systemic
	DUE		bw/day	population	
	DNEL	Long term Dermal	180 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	289 mg/m ³	Workers	Local
	DNEL	Short term Inhalation	289 mg/m ³	Workers	Systemic
1,6-hexanediyl-bis(2-(2-	DNEL	Long term Oral	0.83 mg/	General	Systemic
(1-ethylpentyl)-3-oxazolidinyl)ethyl) carbamate			kg bw/day	population	
	DNEL	Long term	1.25 mg/m ³	General	Systemic
		Inhalation	5	population	,
	DNEL	Long term	5.9 mg/m ³	Workers	Systemic
		Inhalation			-
	DNEL	Long term Dermal	8.3 mg/kg	General	Systemic
		_	bw/day	population	
	DNEL	Long term Dermal	16.7 mg/ kg bw/day	Workers	Systemic
n-butyl acetate	DNEL	Long term Oral	3.4 mg/kg	General	Systemic
-			bw/day	population	-
	DNEL	Long term Dermal	3.4 mg/kg	General	Systemic
		_	bw/day	population	
	DNEL	Long term Dermal	7 mg/kg bw/day	Workers	Systemic
	DNEL	Long term	12 mg/m ³	General	Systemic
		Inhalation	-	population	
	DNEL	Long term Inhalation	48 mg/m³	Workers	Systemic
	DNEL	Long term	102.34 mg/	General	Local
		Inhalation	m³ Ö	population	
	DNEL	Long term Inhalation	480 mg/m ³	Workers	Local
	DNEL	Short term	859.7 mg/	General	Local
		Inhalation	m³ Ö	population	
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m³ Ö	population	-
	DNEL	Short term	960 mg/m ³	Workers	Local
e of issue/Date of revision : 1-11	1-2022		Version	: 1.01	1
					AkzoNob

cyclohexanone DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Cong term Dermal DNEL Cong term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Cong term Dermal DNEL Short term DNEL Cong term DNEL Cong term DNEL Short term DNEL Cong	ECTION 8: Exposure	e controls/p		ction		
cyclohexanone DEEL Short term Dermal 1 mg/kg General Systemic Devices 1 1 mg/kg General Systemic Device 1 Short term 1 0 mg/m ³ General Systemic Device 1 Short term 1 0 mg/m ³ General Systemic Device 1 Short term 1 mg/kg Workers Systemic Inhalation Device 1 Short term 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 mg/kg Workers Systemic Inhalation Device 1 Short term 0 1 0.00 mg/kg General Systemic Inhalation Device 1 Short term 0 1 0.00 mg/kg General Systemic Inhalation Device 1 Short term 0 1 0.00 mg/kg General Systemic Inhalation Device 1 Short term 0 1 0.00 mg/kg General Systemic Inhalation Device 1 Short term 0 mg M M General Systemic Inhalation Device 1 Short term 0 mg M M General Systemic Info Inhalation Device 1 Short term 0 mg M M General Systemic Info Inhalation Device 1 Systemic Info Inhalation Devi		DNEL		960 mg/m ³	Workers	Systemic
Jone L Long term Dermal hmg/kg population Systemic DNEL Short term Oral 1 mg/kg General Systemic DNEL Short term Oral 1 mg/kg Workers Systemic DNEL Long term Oral 1 mg/kg Workers Systemic DNEL Long term Oral 1 mg/kg Workers Systemic DNEL Long term Dermal hmg/kg Workers Systemic DNEL Long term Dermal fmg/kg Workers Systemic DNEL Long term Dermal fmg/kg Workers Systemic DNEL Long term 10 mg/m General Systemic DNEL Long term 20 mg/m General Local DNEL Short term 20 mg/m General Local DNEL Short term 40 mg/m Workers Systemic DNEL Short term 80 mg/m Workers Systemic DNEL Short term 80 mg/m Workers Systemic DNEL Short term 80 mg/m Workers Systemic DNEL Short term 0.02 mg/m Workers Systemic DNEL Short term Dermal 0.2 mg/				Ű		,
DNEL Long term Dermal Img/kg population bw/day General population population population Systemic population DNEL Long term Oral bw/day General population Systemic DNEL Long term Oral bw/day Workers Systemic DNEL Long term Dermal Mg/kg Workers Systemic DNEL Long term 10 mg/m2 General Systemic DNEL Long term 10 mg/m2 General Systemic DNEL Long term 20 mg/m2 General Systemic DNEL Short term 20 mg/m2 General Systemic DNEL Short term 20 mg/m2 General Systemic DNEL Short term 40 mg/m3 General Local DNEL Short term 40 mg/m3 Workers Systemic Inhalation DNEL Short term Dermal mg/kg Workers Systemic Inhalation DNEL Short term Dermal bw/day Workers Systemic DNEL Short term Dermal bw/day General Systemic </td <td>cyclohexanone</td> <td>DNEL</td> <td></td> <td></td> <td></td> <td>Systemic</td>	cyclohexanone	DNEL				Systemic
DNEL DNEL DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Dermal Imalation DNEL Long term Dermal Imalation DNEL Long term Dermal DNEL Long term Dermal Imalation DNEL Long term Dermal DNEL Long term Dermal 		DNEL	Long term Dermal	1 mg/kg	General	Systemic
DNEL Long term Oral 1.5 mg/kg General production population population population population Systemic bw/day DNEL Long term Dermal 4 mg/kg Workers Systemic bw/day DNEL Long term Dermal 10 mg/m ³ General Systemic bw/day DNEL Long term 10 mg/m ³ General Systemic population DNEL Short term 20 mg/m ³ General Systemic population DNEL Short term 20 mg/m ³ General Systemic population DNEL Short term 40 mg/m ³ General Local DNEL Short term 40 mg/m ³ Workers Local DNEL Short term 40 mg/m ³ Workers Systemic Inhalation DNEL Short term 80 mg/m ³ Workers Systemic Inhalation DNEL Short term 0.07 mg/m ³ Workers Systemic Inhalation DNEL Short term 0.07 mg/m ³ General Systemic Inhalation DNEL Short term 0.07 mg/m ³ Workers Systemic DNEL Short term 0.01 mg/m ³ General Systemic DNEL Short term 0.02 mg/m ³ Workers		DNEL	Short term Oral	1.5 mg/kg	General	Systemic
DNEL DNELShort term Dermal Long term Dermal4 mg/kg MorkersWorkersSystemic SystemicDNEL Long term InhalationLong term Dormal10 mg/m³ DormalGeneral population population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic population population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic population DormalSystemic Local population DormalSystemic Local population DormalSystemic Local population Dormal D		DNEL	Long term Oral	1.5 mg/kg	General	Systemic
DNEL Long term 1 mg/kg Workers Systemic DNEL Long term 10 mg/m² General Local population DNEL Long term 20 mg/m² General Local DNEL Long term 20 mg/m² General Local DNEL Short term 40 mg/m² General Local DNEL Long term 40 mg/m² Workers Systemic DNEL Short term 40 mg/m² Workers Systemic DNEL Long term 40 mg/m² Workers Systemic DNEL Long term 40 mg/m² Workers Systemic DNEL Long term 80 mg/m² Workers Systemic Inhalation 10NEL Short term 80 mg/m² Workers Systemic Inhalation 10NEL Short term Dermal 0.07 mg/m² Workers Systemic DNEL Long term 0.01 mg/m² Workers Systemic DNEL Long term Dermal 0.2 mg/m² Workers Systemic DNEL Short term Dermal 0.2 mg/m² Workers Systemic DNEL Short term Oral 0.01 mg/m² General Systemic		DNEL	Short term Dermal	4 mg/kg		Systemic
DNEL Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term DNEL Short term DNEL Long term DNEL Short term DNEL Long term DNEL Short term DNEL DNEL Short term DNEL DNEL DNEL Consumers] Consumers] Consumers] Systemic DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Cong term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL <b< td=""><td></td><td>DNEL</td><td>Long term Dermal</td><td>4 mg/kg</td><td>Workers</td><td>Systemic</td></b<>		DNEL	Long term Dermal	4 mg/kg	Workers	Systemic
DNEL Inhalation Inhalation DNELLong term Inhalation Inhalation DNEL20 mg/m³ population General population General population Doublet Inhalation DNEL Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term DNEL Short term Dermal DNEL Short term Oral DNEL DNEL DNEL DNEL Long term Oral DNEL Consumers] General Systemic population Consumers] Systemic DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL DNEL DNEL Long term Oral DNEL DNEL DNEL Long term Oral DNEL DNEL DNE		DNEL				Systemic
DNEL Inhalation DNEL Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term DNEL Short term DNEL DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL Short term DNEL DNEL DNEL DNEL DNEL DNEL Short term DNEL DNEL Short term DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term O		DNEL	Long term	20 mg/m³	General	Local
DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term DNEL Short term DNEL DNEL Short term DNEL DNEL Short term DNEL DNEL Short term DNEL Short term DNEL Short term DNEL Short term DNEL Short term DNEL Short term DNEL Short term DNEL Short term Dermal DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Oral DNE		DNEL	Short term	20 mg/m³	General	Systemic
DNEL Inhalation InhalationLong term (Inhalation)40 mg/m³WorkersLocalDNEL Inhalation InhalationDNEL InhalationShort term (Inhalation)80 mg/m³WorkersSystemicdibutytin dilaurateDNEL DNEL Short termShort term DNEL Short term Dermal80 mg/m³WorkersSystemicdibutytin dilaurateDNEL DNEL Short term Dermal1 mg/kg bw/dayWorkersSystemicDNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Short term Dermal DNEL DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL Short term Oral DNEL DNEL DNEL DNEL DNEL Short term Oral DNEL DNE		DNEL	Short term	40 mg/m³	General	Local
DNEL Inhalation Inhalation DNELLong term Inhalation Inhalation DNEL40 mg/m³WorkersSystemicdibutyltin dilaurateDNEL Short term Inhalation DNELShort term Inhalation DNEL80 mg/m³WorkersSystemicdibutyltin dilaurateDNEL Short term Inhalation DNELShort term 0.07 mg/m³WorkersSystemicdibutyltin dilaurateDNEL Inhalation DNELShort term Dorem0.07 mg/m³ WorkersWorkersSystemicDNEL Inhalation DNELCong term Dermal Inhalation DNEL0.2 mg/kg bw/day O.01 mg/m³WorkersSystemicDNEL Inhalation DNELShort term Dermal Inhalation DNEL0.5 mg/kg General population [Consumers] GeneralSystemic population [Consumers] General population [Consumers] GeneralSystemic Systemic population [Consumers] General population [Consumers] GeneralSystemic Systemic population [Consumers] General population [Consumers] General population [Consumers] GeneralSystemic Systemic population [Consumers] General population [Consumers] GeneralSystemic Systemic population [Consumers] GeneralSystemic Systemic Systemic population [Consumers] GeneralSystemic Systemic Systemic population [Consumers] GeneralSystemic Systemic Systemic population [Consumers] GeneralSystemic Systemic Systemic Systemic population [Consumers] GeneralSystemic Systemic Systemic Systemic Systemic Systemic Systemic Systemi		DNEL	Long term	40 mg/m³		Local
DNEL Inhalation InhalationShort term Inhalation DNEL Inhalation80 mg/m³ WorkersWorkersLocaldibutyltin dilaurateDNEL DNELShort term DNEL80 mg/m³ UwrkersWorkersSystemicDNEL Inhalation DNELShort term Dermal Inhalation DNEL1 mg/kg bw/day UwrkersWorkersSystemicDNEL Inhalation DNELLong term Inhalation DNEL0.07 mg/m³ WorkersWorkersSystemicDNEL Inhalation DNELLong term Inhalation DNEL0.01 mg/m³ Bw/dayGeneral opulation [Consumers] General population [Consumers] General DNELSystemic Systemic population [Consumers] General population [Consumers] Systemic population [Consumers]<		DNEL	Long term	40 mg/m³	Workers	Systemic
dibutyltin dilaurateInhalation Short term Dermal1 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation DNELShort term Long term Dermal0.07 mg/m³WorkersSystemicDNELLong term Dermal Inhalation DNEL0.11 mg/m³WorkersSystemicDNELLong term Dermal0.2 mg/kg bw/dayWorkersSystemicDNELLong term Dermal0.5 mg/kg bw/dayGeneral population [Consumers]SystemicDNELShort term Dermal0.5 mg/kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELShort term Oral0.01 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Dermal0.08 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.002 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.002 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.004 mg/ general population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.004 mg/ general population [Consumers]Systemic systemicDNELLong term Oral Inhalation DNEL0.004 mg/ general gopulation [Consumers]Systemic systemic <td></td> <td></td> <td>Short term</td> <td>80 mg/m³</td> <td>Workers</td> <td>Local</td>			Short term	80 mg/m³	Workers	Local
DNEL Short term Inhalation 0.07 mg/m³ Workers Systemic DNEL Long term Dermal 0.2 mg/kg bw/day Workers Systemic DNEL Long term 0.01 mg/m³ Workers Systemic DNEL Short term Dermal 0.5 mg/kg General Systemic DNEL Short term Dermal 0.5 mg/kg General Systemic DNEL Short term Oral 0.01 mg/m³ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Long term Dermal 0.08 mg/ General Systemic DNEL Long term Oral 0.003 mg/ General Systemic DNEL Long term Oral 0.002 mg/ General Systemic DNEL Long term Oral 0.004 mg/ General Systemic <td></td> <td></td> <td>Inhalation</td> <td>80 mg/m³</td> <td></td> <td>-</td>			Inhalation	80 mg/m³		-
Inhalation DNEL Long term Dermal 0.2 mg/kg Workers Systemic DNEL Long term 0.01 mg/m³ Workers Systemic DNEL Short term Dermal 0.5 mg/kg General Systemic DNEL Short term Dermal 0.5 mg/kg General Systemic DNEL Short term 0.02 mg/m³ General Systemic DNEL Short term 0.02 mg/m³ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Short term Oral 0.01 mg/ General Systemic DNEL Long term Dermal 0.08 mg/ General Systemic DNEL Long term Oral 0.003 mg/ General Systemic DNEL Long term Oral 0.002 mg/ General Systemic DNEL Long term Oral 0.002 mg/ General Systemic DNEL Long term Oral 0.004 mg/ General Systemic DNEL	dibutyltin dilaurate			bw/day		-
bw/day DNEL Long term Inhalation DNEL Short term Dermal 0.5 mg/kg General population DNEL Short term Dermal 0.5 mg/kg General Systemic population [Consumers] General Systemic population [Consumers] DNEL Short term Oral 0.01 mg/ BNEL Long term Oral 0.01 mg/ General Systemic population [Consumers] DNEL Long term Dermal 0.8 mg/ general Systemic population [Consumers] DNEL Long term Dermal 0.8 mg/ general Systemic population [Consumers] DNEL Long term Oral 0.003 mg/ m³ (General Systemic population [Consumers] DNEL Long term Oral 0.002 mg/ general Systemic population [Consumers] Systemic Systemic population [Consumers] Systemic Systemic population [Consumers] Systemic Systemic population [Consumers] DNEL Long term Oral 0.002 mg/ general Systemic Systemic population [Consumers] Systemic Systemic Sys				-		
Inhalation Short term Dermal0.5 mg/kg bw/dayGeneral population [Consumers]SystemicDNELShort term Inhalation0.02 mg/m³General population [Consumers]SystemicDNELShort term Oral0.01 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.01 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Dermal0.08 mg/ kg bw/dayGeneral population [Consumers]SystemicDNELLong term Dermal0.03 mg/ m³General population [Consumers]Systemic population [Consumers]DNELLong term Oral0.002 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral0.002 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral0.004 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation DNEL0.004 mg/ systemic general populationSystemic population SystemicDNELLong term Oral Inhalation DNEL0.006 mg/ systemicSystemic systemicDNELLong term Oral Inhalation DNEL0.02 mg/ Seneral SystemicSystemic SystemicDNELLong term Oral Inhalation DNEL0.02 mg/ Seneral SystemicSystemic SystemicDNELLong term Oral Inhalation0.02 mg			Long term Dermal	bw/day		-
bw/daypopulation [Consumers] opulation [Consumers]Systemic systemic population [Consumers]DNELShort term Inhalation0.02 mg/m³General gopulation [Consumers]Systemic population [Consumers]DNELShort term Oral0.01 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Dermal Inhalation0.08 mg/ kg bw/dayGeneral population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.003 mg/ m³General general population [Consumers]Systemic population [Consumers]DNELLong term Oral Inhalation0.002 mg/ general generalGeneral Systemic population [Consumers]DNELLong term Oral Inhalation0.004 mg/ general generalSystemic Systemic population [Consumers]DNELLong term Oral Inhalation0.004 mg/ general generalSystemic Systemic population [Consumers]DNELLong term Oral Inhalation0.004 mg/ general generalSystemic Systemic SystemicDNELLong term Inhalation0.02 mg/ BeneralSystemic SystemicDNELLong term Nort term Oral0.02 mg/ BeneralSystemic SystemicDNELLong term Inhalation0.02 mg/ BeneralSystemic SystemicDNELShort term Oral0.02 mg/ BeneralSystemic SystemicDNELLong term Inhalation0.02 mg/ Beneral <td< td=""><td></td><td></td><td>Inhalation</td><td>-</td><td></td><td>-</td></td<>			Inhalation	-		-
DNEL Short term Inhalation 0.02 mg/m³ General population [Consumers] Systemic DNEL Short term Oral 0.01 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Dermal 0.08 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Dermal 0.03 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.003 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.002 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.004 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.004 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.004 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.002 mg/ Beneral Systemic Systemic DNEL Long term Inhalation 0.02 mg/ Beneral Systemic Systemic DNEL Short term Oral 0.02 mg/ Beneral Systemic Systemic </td <td></td> <td>DNEL</td> <td>Short term Dermal</td> <td></td> <td>population</td> <td>Systemic</td>		DNEL	Short term Dermal		population	Systemic
DNELShort term Oral0.01 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Dermal0.08 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Inhalation0.003 mg/ m³General population [Consumers]]SystemicDNELLong term Inhalation0.002 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.002 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.004 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.004 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.004 mg/ kg bw/dayGeneral population [Consumers]]SystemicDNELLong term Oral0.004 mg/ population [Consumers]]SystemicDNELLong term Inhalation DNEL0.02 mg/ BeneralGeneral population Systemice of issue/Date of revision:1-11-2022Version:1.01		DNEL		0.02 mg/m ³	General population	Systemic
DNEL Long term Dermal 0.08 mg/ kg bw/day General population [Consumers]] Systemic DNEL Long term Inhalation 0.003 mg/ m³ General population [Consumers]] Systemic DNEL Long term Oral 0.002 mg/ kg bw/day General population [Consumers]] Systemic DNEL Long term Oral 0.002 mg/ kg bw/day General population [Consumers]] Systemic DNEL Long term Oral 0.004 mg/ kg bw/day General population [Consumers]] Systemic DNEL Long term Oral 0.006 mg/ n³ General population Systemic DNEL Long term 0.006 mg/ n³ General population Systemic DNEL Short term Oral 0.02 mg/ General general Systemic version :1.01 Systemic Systemic		DNEL	Short term Oral		General population	Systemic
DNEL Long term 0.003 mg/ General Systemic Inhalation m³ General population [Consumers]] DNEL Long term Oral 0.002 mg/ General Systemic DNEL Long term Oral 0.004 mg/ General Systemic DNEL Long term Oral 0.004 mg/ General Systemic DNEL Long term Oral 0.006 mg/ General Systemic DNEL Long term 0.006 mg/ General Systemic DNEL Long term 0.006 mg/ General Systemic DNEL Short term Oral 0.02 mg/ General Systemic DNEL Short term Oral 0.02 mg/ General Systemic population DNEL Short term Oral 0.02 mg/ General Systemic		DNEL	Long term Dermal		General population	Systemic
DNEL Long term Oral 0.002 mg/ kg bw/day General population [Consumers] Systemic DNEL Long term Oral 0.004 mg/ kg bw/day General population Systemic DNEL Long term Oral 0.006 mg/ n³ General population Systemic DNEL Long term Inhalation DNEL Short term Oral 0.006 mg/ 0.02 mg/ General general Systemic e of issue/Date of revision :1-11-2022 Version :1.01		DNEL		-	General population	Systemic
DNEL Long term Oral 0.004 mg/ kg bw/day General population Systemic DNEL Long term Inhalation 0.006 mg/ m³ General population Systemic DNEL Short term Oral 0.02 mg/ General Systemic e of issue/Date of revision : 1-11-2022 Version : 1.01		DNEL	Long term Oral		General population	Systemic
DNEL Long term 0.006 mg/ General Systemic Inhalation DNEL Short term Oral 0.02 mg/ General Systemic e of issue/Date of revision : 1-11-2022 Version : 1.01		DNEL	Long term Oral	•	General	Systemic
DNEL Short term Oral 0.02 mg/ General Systemic e of issue/Date of revision :1-11-2022 Version :1.01		DNEL		0.006 mg/	General	Systemic
		DNEL				Systemic
e of previous issue : 1-10-2022 9/20 AkzoNot	e of issue/Date of revision	: 1-11-2022		Version	: 1.01	
	e of previous issue	:1-10-2022		9/20		AkzoNob

SECTION 8: Exposure controls/personal protection						
		kg bw/day	population			
DNEL	Long term Inhalation	0.02 mg/m ³	Workers	Systemic		
DNEL	Short term Inhalation	0.04 mg/m ³	General population	Systemic		
DNEL	Long term Dermal	0.16 mg/ kg bw/day	General population	Systemic		
DNEL	Long term Dermal	0.42 mg/ kg bw/day	Workers	Systemic		
DNEL	Short term Dermal	1 mg/kg bw/day	General population	Systemic		
DNEL	Short term Dermal	2.08 mg/ kg bw/day	Workers	Systemic		

PNECs

Product/ingredient name	Compartment Detail	Value	Method Detail
dibutyltin dilaurate	Fresh water Marine water Fresh water sediment	0.463 µg/l 0.0463 µg/l 0.05 mg/kg	
	Marine water sediment Soil Sewage Treatment Plant	0.005 mg/kg 0.0407 mg/kg 100 mg/l	-

8.2 Exposure controls

: Use only with adequate ventilation. Use process enclosures, local exhaust Appropriate engineering ventilation or other engineering controls to keep worker exposure to airborne controls contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

Individual protection measures

Hygiene measures	before eating, smokin Appropriate technique Contaminated work cl contaminated clothing	s and face thoroughly after handling g and using the lavatory and at the e es should be used to remove potentia othing should not be allowed out of t before reusing. Ensure that eyewa the workstation location.	ally contaminated clothing. the workplace. Wash
Eye/face protection	assessment indicates gases or dusts. If cor	lying with an approved standard sho this is necessary to avoid exposure ttact is possible, the following protec nt indicates a higher degree of protec	to liquid splashes, mists, tion should be worn,
Skin protection			
Hand protection	be worn at all times w this is necessary. Co check during use that should be noted that t different for different g	Chemical-resistant, impervious gloves complying with an approved standard shound be worn at all times when handling chemical products if a risk assessment indicated this is necessary. Considering the parameters specified by the glove manufacture check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.	
	protection class of 6 (recommended. Reco When only brief conta (breakthrough time >3 Recommended glove	equently repeated contact may occu breakthrough time >480 minutes acc mmended gloves: Viton \circledast or Nitrile, ct is expected, a glove with protection 30 minutes according to EN374) is re s: Nitrile, thickness ≥ 0.12 mm. aced regularly and if there is any sig	cording to EN374) is thickness ≥ 0.38 mm. on class of 2 or higher ecommended.
Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	10/20	AkzoNobel

zoNobe
i

SECTION 8: Exposure controls/personal protection

	material.
	The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
	The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Partition coefficient: n-octanol/ water	: Not available.		
Density Solubility(ies)	 1.038 g/cm³ Insoluble in the following material 	ls: cold water.	
Vapor density	: Highest known value: 4.1 (Air = 7 average: 3.77 (Air = 1)	1) (1,2,4-trimethylbenzene).	Weighted
Vapor pressure	: Not available.		
Upper/lower flammability or explosive limits	: Not available.		
Flammability (solid, gas)	: Not available.		
Evaporation rate	: Not available.		
Flash point	: Closed cup: 44°C		
Initial boiling point and boiling range	: Not available.		
Melting point/freezing point	: Not available.		
рН	: Not available.		
Odor threshold	: Not available.		
Odor	: Characteristic.		
Physical state Color	: Liquid. : Gray.		
Appearance			
	Liquid		

SECTION 9: Physical and chemical properties

SECTION 10: Stabilit	y and reactivity
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
Reaction mass of	LC50 Inhalation Gas.	Rat	5000 ppm	4 hours
ethylbenzene and xylene				
n-butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
	LC50 Inhalation Vapor	Mouse	6 g/m³	2 hours
	LD50 Dermal	Rabbit	>17600 mg/kg	-
	LD50 Intraperitoneal	Mouse	1230 mg/kg	-
	LD50 Oral	Guinea pig	4700 mg/kg	-
	LD50 Oral	Mouse	6 g/kg	-
	LD50 Oral	Rabbit	3200 mg/kg	-
	LD50 Oral	Rat	10768 mg/kg	-
cyclohexanone	LC50 Inhalation Gas.	Rat	8000 ppm	4 hours
	LD50 Dermal	Rabbit	1 mL/kg	-
	LD50 Intraperitoneal	Guinea pig	930 mg/kg	-
	LD50 Intraperitoneal	Mouse	1230 mg/kg	-
	LD50 Intraperitoneal	Mouse	1230 mg/kg	-
	LD50 Intraperitoneal	Rabbit	1540 mg/kg	-
	LD50 Intraperitoneal	Rabbit	1540 mg/kg	-
	LD50 Intraperitoneal	Rat	1130 mg/kg	-
	LD50 Intraperitoneal	Rat	1130 mg/kg	-
	LD50 Oral	Mouse	1400 mg/kg	-
	LD50 Oral	Rat	1800 mg/kg	-
	LD50 Oral	Rat	1620 uL/kg	-
	LD50 Subcutaneous	Rat	2170 mg/kg	-
dibutyltin dilaurate	LC50 Inhalation Dusts and	Mouse	150 mg/m ³	2 hours
-	mists		_	
	LD50 Intraperitoneal	Mouse	180 mg/kg	-
	LD50 Intravenous	Rat	33 mg/kg	-
	LD50 Oral	Mouse	210 mg/kg	-
	LD50 Oral	Rabbit	100 mg/kg	-
	LD50 Oral	Rat	175 mg/kg	-
Conclusion/Summary	: Not available.	I		- 1

Irritation/Corrosion



SECTION 11: Toxicological information

Product/ingredient name	Result	Species	Score	Exposure	Observation
Reaction mass of ethylbenzene and xylene	Eyes - Mild irritant	Rabbit	-	87 mg	-
	Eyes - Severe irritant	Rabbit	-	24 hours 5 mg	-
	Skin - Mild irritant	Rat	-	8 hours 60 UI	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500 mg	-
	Skin - Moderate irritant	Rabbit	-	100 %	-
n-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500 mg	-
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250 ug	-
	Eyes - Severe irritant	Rabbit	-	20 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
Conclusion/Summary	: Not available.				
<u>Sensitization</u>					
Conclusion/Summary	: Not available.				
<u>Mutagenicity</u>					
Conclusion/Summary	: Not available.				
Carcinogenicity					
Conclusion/Summary	: Not available.				
Reproductive toxicity					
Conclusion/Summary	: Not available.				
Teratogenicity					

Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 3	-	Respiratory tract irritation
aromatic hydrocarbons, C9	Category 3	-	Respiratory tract irritation
	Category 3		Narcotic effects
n-butyl acetate	Category 3	-	Narcotic effects
dibutyltin dilaurate	Category 1	-	thymus

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
	Category 2 Category 1	-	- immune system

Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene aromatic hydrocarbons, C9 Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

Information on the likely : Not available. routes of exposure



SECTION 11: Toxicological information

Detertial caute health affect	
Potential acute health effect	-
Eye contact	: Causes serious eye irritation.
Inhalation	: Harmful if inhaled. May cause respiratory irritation.
Skin contact	: Causes skin irritation. May cause an allergic skin reaction.
Ingestion	: No known significant effects or critical hazards.
Symptoms related to the phy	sical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	 Adverse symptoms may include the following: respiratory tract irritation coughing
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	ts and also chronic effects from short and long term exposure
<u>Short term exposure</u>	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: May cause damage to organs through prolonged or repeated exposure. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.



SECTION 12: Ecological information

Product/ingredient name	Result	Species	Exposure
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
n-butyl acetate	Acute LC50 32 mg/l Marine water Acute LC50 100000 µg/l Fresh water Acute LC50 18000 µg/l Fresh water Acute LC50 185000 µg/l Marine water Acute LC50 62000 µg/l Fresh water	Crustaceans - Artemia salina Fish - Lepomis macrochirus Fish - Pimephales promelas Fish - Menidia beryllina Fish - Danio rerio	48 hours 96 hours 96 hours 96 hours 96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water Acute LC50 630000 µg/l Fresh water Acute LC50 527000 µg/l Fresh water Acute LC50 732000 µg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase Fish - Pimephales promelas Fish - Pimephales promelas Fish - Pimephales promelas	72 hours 96 hours 96 hours 96 hours

Conclusion/Summary : Not available.

12.2 Persistence and degradability

Conclusion/Summary : Not available.

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
n-butyl acetate	2.3 0.86	-	low low
cyclohexanone dibutyltin dilaurate	4.44	- 2.91	low

12.4 Mobility in soil	
Soil/water partition	: Not available.
coefficient (Koc)	
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Other adverse effects : No known significant effects or critical hazards.

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.

SECTION 13: Disposal considerations

Disposal considerations	: Do not allow to enter drains or watercourses.
	Dispose of according to all federal, state and local applicable regulations.
	If this product is mixed with other wastes, the original waste product code may no
	longer apply and the appropriate code should be assigned.
	For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Disposal considerations	 Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	IMDG	ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT	PAINT	PAINT
14.3 Transport hazard class(es)	3	3	3
14.4 Packing group	111		
14.5 Environmental hazards	No.	No.	No.

Additional information

ADR/RID

 Viscous liquid exception This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1.
 Tunnel code (D/E)

IMDG

: <u>Emergency schedules</u> F-E, _S-E_ <u>Viscous liquid exception</u> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.3.2.5.



	MAPCOAT DASE GRET ASOTO
SECTION 14: Transp	ort information
14.6 Special precautions for user	: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
14.7 Transport in bulk according to IMO instruments	: Not applicable.
SECTION 15: Regula	tory information
EU Regulation (EC) No. 190	onmental regulations/legislation specific for the substance or mixture 7/2006 (REACH) nces subject to authorization
Annex XIV	
None of the components a	e listed.
Substances of very high	<u>concern</u>
None of the components a	e listed.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.
Other EU regulations	
VOC	: The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information.
VOC for Ready-for-Use Mixture	: Not applicable.
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed
Industrial emissions (integrated pollution prevention and control) - Water	: Not listed
Ozone depleting substanc	es (1005/2009/EU)
Not listed.	

Prior Informed Consent (PIC) (649/2012/EU)

Ingredient name	Annex	Status
dibutyltin dilaurate Annex I - Part 1		Listed

Seveso Directive

This product is controlled under the Seveso Directive.

Danger criteria

Category	
P5c	
National regulations	
Industrial use	• The information contained in this safety data sheet does not constitute the user's

Industrial use : The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	17/20	AkzoNobel

	MAPCOAT BASE GREY A3610	
SECTION 15: Regula	tory information	
Social Security Code, Articles L 461-1 to L 461-7	: Reaction mass of ethylbenzene and xylene n-butyl acetate cyclohexanone	RG 4bis, RG 84 RG 84 RG 84
Reinforced medical surveillance	: Decree n ° 2012-135 of January 30, 2012 relating t occupational medicine: not applicable	to the organization of
International regulations Chemical Weapon Convent	on List Schedules I, II & III Chemicals	
Not listed.		
Montreal Protocol Not listed.		
Stockholm Convention on F Not listed.	Persistent Organic Pollutants	
Rotterdam Convention on F Not listed.	rior Informed Consent (PIC)	
UNECE Aarhus Protocol on Not listed.	POPs and Heavy Metals	
<u>Inventory list</u> Europe	: Not determined.	
15.2 Chemical Safety Assessment	: No Chemical Safety Assessment has been carried	out.
SECTION 16: Other i	nformation	
Indicates information that h	as changed from previously issued version.	
Abbreviations and acronyms	: ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Reg 1272/20081	gulation [Regulation (EC) No.

 SECTION 16: Other information Indicates information that has changed from previously issued version. 		
Procedure used to derive the	e classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]	

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Acute Tox. 4, H332	Calculation method
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
Skin Sens. 1, H317	Calculation method
STOT SE 3, H335	Calculation method
STOT RE 2, H373	Calculation method
Aquatic Chronic 3, H412	Calculation method

Full text of abbreviated H statements

	MAPCOAT BASE GREY A3610
SECTION 16: Other info	rmation
H226	Flammable liquid and vapor.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H341	Suspected of causing genetic defects.
H360FD	May damage fertility. May damage the unborn child.
H370	
	Causes damage to organs.
H372	Causes damage to organs through prolonged or repeated
11070	exposure.
H373	May cause damage to organs through prolonged or repeated
11400	exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.
Full text of classifications [CLP/G	SHS]
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	AQUATIC HAZARD (ACUTE) - Category 1
Aquatic Chronic 1	AQUATIC HAZARD (LONG-TERM) - Category 1
Aquatic Chronic 2	AQUATIC HAZARD (LONG-TERM) - Category 2
Aquatic Chronic 3	AQUATIC HAZARD (LONG-TERM) - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Muta. 2	GERM CELL MUTAGENICITY - Category 2
Repr. 1B	TOXIC TO REPRODUCTION - Category 1B
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITIZATION - Category 1
STOT RE 1	SPECIFIC TARGET ORGAN TOXICITY (REPEATED
	EXPOSURE) - Category 1
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY (REPEATED
	EXPOSURE) - Category 2
STOT SE 1	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) -
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) -
	Category 3
Date of printing : 1	1 November 2022

Date of issue/ Date of revision	: 1 November 2022
Date of previous issue	: 1 October 2022
Version	: 1.01
Unique ID	:

Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless

Date of issue/Date of revision	: 1-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	19/20	A



Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 MAPCOAT BASE GREY A3610

SECTION 16: Other information

we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

